- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02502162
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome (LDN-CRPS)
November 15, 2023 updated by: Sean Mackey, Stanford University
The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS).
Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks.
During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Birute Gedrimaite
- Phone Number: (650) 497-0485
- Email: birute@stanford.edu
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Recruiting
- Stanford University
-
Contact:
- Birute Gedrimaite
- Phone Number: 650-497-0485
- Email: birute@stanford.edu
-
Principal Investigator:
- Sean Mackey, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Upper and/or lower extremity CRPS
- On stable treatment for 1 month
- CRPS for at least 1 year
- Meet the Budapest criteria for CRPS at time of the study.
Exclusion Criteria:
- Any known allergy to naltrexone or naloxone
- Use of prescription opioid analgesics or illegal opioid use
- Current or planned pregnancy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Sugar pill
|
Sugar pill
|
Experimental: LDN
Naltrexone HCL, 4.5 mg, Once a day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in pain severity
Time Frame: Approximately 4 weeks after conclusion of treatment.
|
Daily pain reports on a 0-10 numerical rating scale for pain, where 0=no pain and 10=pain as bad as you can imagine
|
Approximately 4 weeks after conclusion of treatment.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sean Mackey, MD, PhD, Stanford University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2015
Primary Completion (Estimated)
June 1, 2025
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
July 15, 2015
First Submitted That Met QC Criteria
July 16, 2015
First Posted (Estimated)
July 20, 2015
Study Record Updates
Last Update Posted (Estimated)
November 17, 2023
Last Update Submitted That Met QC Criteria
November 15, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 33607
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Complex Regional Pain Syndrome
-
University of Sao PauloUniversity of Sao Paulo General HospitalUnknownComplex Regional Pain Syndrome I of Upper LimbBrazil
-
Ruhr University of BochumUnknownComplex Regional Pain Syndrome Type I of the Upper LimbGermany
-
University of ZurichBalgrist University HospitalRecruitingComplex Regional Pain Syndrome I (CRPS I) | Complex Regional Pain Syndromes | Osteoarthritis Hand | Complex Regional Pain Syndrome Type II | Complex Regional Pain Syndrome Type I of the Upper Limb | Complex Regional Pain Syndrome I of Upper Limb | Complex Regional Pain Syndrome II of Upper Limb | Peripheral Nerve Injury Upper Limb and other conditionsSwitzerland
-
Hospital for Special Surgery, New YorkNot yet recruitingChronic Pain | Complex Regional Pain Syndrome | Causalgia | Complex Regional Pain Syndrome Type I | Complex Regional Pain Syndrome Type IIUnited States
-
University of GroningenWithdrawnComplex Regional Pain Syndrome Type I of the Upper LimbNetherlands
-
Grünenthal GmbHTerminatedComplex Regional Pain Syndrome (CRPS)United States, Australia, France, Germany, Korea, Republic of, New Zealand, Spain
-
The Cleveland ClinicMurdoch UniversityTerminatedComplex Regional Pain Syndrome (CRPS)United States
-
Stanford UniversityCompletedComplex Regional Pain Syndrome (CRPS)United States
-
Stanford UniversityCompleted
-
Vibhor KrishnaMedtronicCompletedComplex Regional Pain Syndrome (CRPS) | Neuropathic Leg PainUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States